just.....which was confirmed to me recently as the HOLY GRAIL which IPIX still owns!
What an incredible piece of news! I was unaware. Thank you!
Slcimmuno...excellent digging...for newbies... I will add (IPIX) since IPIX is the owner of PolyMedix's patent filings...but a hidden GEM is in there...which was confirmed to me recently as the HOLY GRAIL which IPIX still owns!
"DeNovo Compound Design
PolyMedix (IPIX) is developing proprietary computational and synthetic chemistry approaches that we believe should be broadly applicable to developing novel small molecule therapeutic drugs for transmembrane protein targets and protein:protein interactions. The compounds and methods of design are de novo and proprietary, and provide a unique platform for the design of compounds that have been difficult to develop using traditional small molecule approaches. PolyMedix’s protein computational technologies were developed at the University of Pennsylvania.
PACE®
One of our de novo drug design non-downloadable software tools is called PACE®: Proteomic Assisted Computational Engine. PACE® is one of the non-downloadable software models we use in our de novo drug design and it is explained below.
Quote:Our computational methodologies will be kept as proprietary trade secrets of PolyMedix. (AND THEY ARE OWNED BY IPIX!!! (RECENTLY CONFIRMED BY DR. DeGRADO as STILL IN EFFECT)
However, PolyMedix anticipates forming collaborations to develop drugs and targets for partners using its technologies.
De novo Design
PolyMedix’s lead scientific founder, Dr. William F. DeGrado, is well known as the pioneer of de novo design, an approach that involves the design of bioactive molecules from first principles. De novo design begins with a given molecular framework, and then adds functional groups (chemical appendages) to introduce properties of interest. As described below, de novo design involves three basic steps:..."
Market Data 
Markets 
AI
